The recent partnership between xCures and Travera could identify new options for advanced carcinoma patients and their physicians..
Travera has developed TraveraRTGx which examines how a patient’s live tumor cells or immune cells may uniquely respond to certain approved anti-cancer therapies, including advanced immunotherapies.
Travera RTGx is for carcinoma using malignant fluid from pleural effusion or ascites, body fluids that have cancer cells in them and that are often collected by doctors.
